|
Δευτέρα 2 Μαΐου 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Pycnodysostosis is a rare autosomal, recessive, skeletal dysplasia caused by a mutation in the cathepsin k gene. Pycnodysostosis is characte...
-
2016-12-10T02-17-59Z Source: Indo American Journal of Pharmaceutical Research Radha S & Sreelatha .S*. Research has demonstrated th...
-
ACS Nano DOI: 10.1021/acsnano.7b01783 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2trY7nv via...
-
Need Industrial relations advice? Unfair dismissals laws? Discrimination in the workplace? Sexual harassment? We can help. AWNA is Australia...
-
Participant Experiences of Attending a Community CBT Workshop for Insomnia: A Qualitative Six-Year Follow-Up. Behav Sleep Med. 2017 Ap...
-
Persuasive speech ideas - 50+ provoking, fresh ideas to help you find the persuasive speech topic best suited to you and your audience. fr...
-
Description A Caucasian boy aged 5 years presented with acute onset of a non-tender, palpable purpuric rash to his lower limbs, preceded by ...
-
Publication date: Available online 10 February 2017 Source: Brachytherapy Author(s): M.F. Jamaluddin, S. Ghosh, M.P. Waine, M. Tavakoli, J...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου